REVIVE is an international multi-centre trial to evaluate azithromycin prophylaxis to reduce excess mortality among people with advanced HIV disease and CD4 count of 100 cells/mm3 or less.
Azithromycin, provided for 4 weeks together with antiretroviral therapy, will be compared with matching placebo and given on a background of standard of care for advanced HIV disease, as determined by relevant local guidelines.
All-cause mortality at 24 weeks after randomization
• All-cause mortality at 12 weeks
• Hospitalization at 24 weeks
• Composite of hospitalization and all-cause mortality at 24 weeks
Sub-studies will evaluate additional outcomes of interest including cause of death and carriage of antimicrobial resistant pathogens, as well cost-effectiveness of azithromycin.
For inquiries about the REVIVE study, please don’t hesitate to reach out to the research team at email@example.com.REVIVE design and countries
Double blinded, placebo-controlled
6 (vanguard); 13 (main trial)
20 (vanguard); 150 (main trial)
Population Health Research Institute
John Eikelboom is Associate Professor in the Department of Medicine, McMaster University, and a haematologist in the Thrombosis Service, Hamilton General Hospital. He originally trained in Internal Medicine and Haematology in Perth, Australia and subsequently moved to Hamilton to take up a Tier II Canada Research Chair in Cardiovascular Medicine.
He has co-authored more than 350 articles in peer-reviewed journals. His current research, supported by the Canadian Institutes for Health Research, the Heart and Stroke Foundation and the National Health and Medical Research Council of Australia, focuses on the efficacy and safety of antithrombotic therapies, outcomes after blood transfusion and bleeding, and the mechanisms of variable response to antiplatelet drugs.
Thomas Scheier, an infectious diseases physician, is a MSc student in the Health Research Methodology Program at McMaster University (supervised by Associate PHRI Scientist Dominik Mertz).
His research interests include antimicrobial resistance, infection control, and hospital epidemiology. Supervised by PHRI Senior Scientist John Eikelboom, he is project officer of the REVIVE trial.
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
Back To Top